ZOLL Medical Corp (NASDAQ:ZOLL)
The Company develops technologies and software that help clinicians, emergency medical services personnel and lay rescuers advance the practice of resuscitation.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
High Public Opinion with Low Relative Strength
Recs
Outperform, there is a big need in the medical field for equipment.
Recs
what can you say?
$60M in Cash, No debt, LT growth in sales.
Hopefully the profit growth will follow. Margins are the one thing they seem to be missing. Some recovery in muni spending should drive this thing.
Recs
sell it
Recs
Just like Medtronic, Zoll is at the forefront of the defibrillation and cardiac monitoring market. New technology, features and recent successes make Zoll the manufacturer to watch. If an agency doesn't buy a Lifepak, chances are, they're buying a Zoll. Cover all the options and buy both companies...
Recs
Growing market share and bottom line. Adding plant and personnel assets.
Recs
good momentum - looks like it will breakout
Recs
Management seems very solid and delivers what it says it will. Good position competitively
Recs
ZOLL has reasonable fundamentals and looks like it is ready to bounce technically also. I don't have a strong fundamental feel for the demand for their business (medical equipment) so I'm going purely on projected earnings and technicals on this one.
Recs
this stock falls under my beatdown coiled spring theory
Recs
Recs
ZOLL Medical (ZOLL) develops technologies and software that help clinicians, emergency medical services (EMS) personnel and lay rescuers advance the practice of resuscitation. Its line of resuscitation products includes professional defibrillators, automated external defibrillator (AED), AutoPulse Non-invasive Cardiac Support Pump, documentation and information management, fluid replacement, and disposable electrodes. Also it has a subsidiary company Lifecor Inc. that designs, manufactures and markets a wearable external defibrillator system (Lifevest).
ZOLL’s market is divided into three geographic categories North American hospital; North American pre-hospital, which consists of an EMS and public-access component and international market. Hospitals are looking for new technologies that can help them protect patients from Sudden Cardiac Arrest (SCA). As a result, hospitals are installing defibrillators with AED capability in clinical areas. These factors augur well for the company. Also, international market’s use of defibrillators outside the hospitals is generally less developed than in North America.
Company’s financials are showing good rising trend with increase in all its categories for past three fiscal years. This was further supported by rise in net profit by almost 100% due to higher North American Hospital market sales and rise in income from pre-hospital North American market in the first quarter 2007 over the last year. Also company began shipping AutoPulse to distribution partners in Japan, which will give stability to its top-line.
The negative news about the leading player Medtronic’s Physio-Control businesses non-shipment status is showing positive signs for the company. Here, ZOLL is viewed as a likely alternative and a ready partner. Further, the scrip liquidity is likely to rise in the future with recent announcement of stock split. All the current development shows an increasing trend for the stock price in the near future.
Recs
Had a nice run up with new drug approval - and is now on the radar scope. Should continue to turn in good results better than the market.
Recs
very defensive stock in which they produce exactly what business have to have by law in there bulidings. It is also on calender to split on Feb 26. If you buy you must stay because it will only grow faster then you can count the money you make from the previous split
Recs
hospitals and ambulances are loading up on defibs as part of their focus on improving the amount of time it takes to provide cardiac care.
Recs
There difribulators are the best with the ability to keep reading body stats while being used. Hospitals and ambulance services are eating these up.
Recs
5-star $503 million market cap on 11/25/06.
Resuscitation products and software.
5STARsmallCAPS picks five star stocks with the smallest market caps.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 17 of 17